https://www.businesswire.com/news/home/20221108005267/en/New-Inventprise-Pneumococcal-Vaccine-Enters-Phase-12-Clinical-Evaluation
0
0
11/10/22 at 10:30am
Organization
Business Wire
36 words
0
Comments
Biotechnology company Inventprise today announced that a Phase 1/2 clinical study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) has beg
You are the first to view
Create an account
or login to join the discussion